Dova Pharmaceuticals, Inc. Common Stock
DOVA
DOVA was delisted on the 11th of November, 2019.
55 hedge funds and large institutions have $275M invested in Dova Pharmaceuticals, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 5 reducing their positions, and 7 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 5
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
32% more capital invested
Capital invested by funds: $209M → $275M (+$66.7M)
15% more funds holding
Funds holding: 48 → 55 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$29.1M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.3M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$5.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
-$13.2M |
| 2 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$346K |
| 3 |
VF
Virtu Financial
New York
|
-$339K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$204K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$48.7K |
DOVA Hedge Fund Activity: Q1 2018 in Review
55 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q1 2018, worth a combined $275M — up 32% from $209M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new DOVA positions and 7 closed out — a net gain of 8 holders — while 25 added to existing stakes and 5 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $29.1M. The largest seller was Paulson & Co, exiting entirely with an estimated $13.2M sold.
- 55 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q1 2018, up from 48 in Q4 2017.
- Funds reported $275M of Dova Pharmaceuticals, Inc. Common Stock stock for Q1 2018, up 32% quarter-over-quarter.
- 15 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q1 2018 and 7 closed out, a net change of +8 holders.
- The largest Dova Pharmaceuticals, Inc. Common Stock buyer in Q1 2018 was Perceptive Advisors, an estimated $29.1M added.
- The largest Dova Pharmaceuticals, Inc. Common Stock seller in Q1 2018 was Paulson & Co, an estimated $13.2M sold.
Based on aggregated 13F filings for Q1 2018.